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Abstract
Inhibition of fungal lanosterol-14a-demethylase (CYP51) is the working principle of the antifungal activity of azoles used in
agriculture and medicine. Inhibition of human CYP51 may result in endocrine disruption since follicular fluid-meiosis activating
steroid (FF-MAS), the direct product of lanosterol demethylation, is involved in the control of meiosis. To investigate the specificity
of antifungal agents for the fungal enzyme, assays to determine inhibitory potencies of 13 agricultural fungicides and 6 antimycotic
drugs were established. FF-MAS product formation was measured by LC–MS/MS analysis in the incubations using lanosterol as
substrate. Recombinant human enzyme (hCYP51) was available from BD Gentest. CYP51 of Candida albicans (cCYP51) was
co-expressed with Candida tropicalis oxidoreductase in the baculovirus system. IC50 values of 13 fungicides for cCYP51 ranged
about six-fold (0.059–0.35mM); for hCYP51 the range was about 30-fold (1.3–37.2mM). The most favourable IC50 ratio human to
Candida was observed for imazalil (440-fold), while the specificity of epoxiconazole and tebuconazole for cCYP51 was only by a
factor of 10. For the antimycotic drugs, the range of IC50 values for cCYP51 was similar to those of fungicides (0.039–0.30mM). For
the inhibition of hCYP51, IC50 values split into two classes: the newer drugs fluconazole and itraconazole showed little inhibition
(≥30mM) while the older drugs were even more potent than the agricultural fungicides, with miconazole being the most potent
(0.057mM). No correlation was seen between the IC50 values determined for the two enzymes, indicating that a housekeeping gene
can show significant diversity if inhibition is concerned. Our data indicate that fungicide residues in food are unlikely to exert a
relevant inhibition of CYP51 in humans whereas systemic use of some antimycotic drugs, e.g. ketoconazole or miconazole, should
be carefully considered regarding disturbance of human steroid biosynthesis.
© 2006 Published by Elsevier Ireland Ltd.
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1. Introduction
Cytochrome P450 monooxygenases (CYPs) form
a large group of enzymes found in most organisms
from bacteria to mammals and can be grouped into
281 families (Nelson, 2006; Lepesheva and Waterman,
2004). According to their function CYPs can be
0300-483X/$ – see front matter © 2006 Published by Elsevier Ireland Ltd.
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classified into enzymes metabolizing xenobiotics
(e.g. CYP3A4, CYP2D6) and enzymes that are part
of key biosynthetic pathways (e.g. steroid genesis),
with a narrow substrate specificity (Lepesheva and
Waterman, 2004). Cytochrome P450 isoenzyme 51
(CYP51/lanosterol-14a-demethylase) is a family of
phylogenetic highly conserved monooxygenases found
in mycobacteria, fungi, plants, animals and humans
(Lepesheva and Waterman, 2004). In mammals and
yeasts it catalyzes the three-step oxidative removal of
the methyl group #32 of lanosterol to produce follicular
fluid-meiosis activating steroid (FF-MAS), an important
step in sterol biosynthesis (Rozman and Waterman,
1998). In fungi, subsequent steps result in ergosterol, an
essential compound of the fungal cell membrane. The
working principle of azoles as fungicides relies on the
inhibition of CYP51, thus fungi lack ergosterol, which
leads to a collapse of the cell membrane.
In animals and humans, a downstream product of
lanosterol-14a-demethylation is cholesterol, which is
necessary for the synthesis of bile acids, mineralo-
corticoids, glucocorticoids and sex steroids. While
cholesterol can, in principle, be supplemented with food
intake, inhibition of CYP51 results in a lack of FF-MAS
and its following metabolite testis-meiosis activating
steroid (T-MAS). These direct products of the CYP51
reaction act as meiosis-activating steroids on ovaries
and testes (Byskov et al., 2002) so that inhibition of
CYP51 in human may affect the endocrine system (Zarn
et al., 2003).
The ideal antifungal agent should be a potent inhibitor
of fungal CYP51 while leaving the human CYP51 unaf-
fected. Human CYP51 has been co-expressed in the
baculovirus system with the respective human oxidore-
ductase and is available for the comparison of azoles for
their inhibitory potency (Trosken et al., 2004b). CYP51
of Candida albicans has been previously cloned and
expressed in yeast and bacterial expression systems
(Lamb et al., 1999b; Lepesheva et al., 2001).
Several CYPs have been successfully expressed in
the baculovirus system (Crespi and Miller, 1999). This
system has the distinct advantages combining very high
expression levels with the fidelity of an eukaryontic
folding and posttranslational modification machinery.
In addition two proteins can be uncertainly expressed
with equally high expression levels. Cytochrome P450
enzymes are membrane bound enzymes requiring
the presence of a NADPH oxidoreductase to be
catalytically active. To obtain a functional enzyme the
CYP can be expressed alone and reconstituted later
with the oxidoreductase or the CYP is co-expressed
with the oxidoreductase on the same virus construct
(Buters et al., 1994; Chen et al., 1997; Lee et al.,
1995).
Up to now C. albicans CYP51 has not been co-
expressed as a fusion protein with a respective oxidore-
ductase. To compare the inhibitory potency of azoles
on human CYP51 and fungal CYP51, C. albicans
CYP51 (Lepesheva et al., 2001) and Candida tropicalis
cytochrome P450 oxidoreductase (Sutter et al., 1990)
were co-expressed in the baculovirus system to obtain
a functional CYP51 enzyme with a similar background
as the human enzyme. C. tropicalis oxidoreductase was
chosen as the closest available relative to the C. albicans
oxidoreductase.
FF-MAS product formation and substrate concentra-
tion in the incubation assays was monitored directly
by liquid chromatography tandem mass spectrometry
(LC–MS/MS) with protein precipitation and centrifu-
gation as only sample work-up steps (Trosken et al.,
2004b).
Nineteen different antifungal agents (13 used agricul-
turally, 6 used in human medicine) were tested for their
inhibitory potencies on human and C. albicans CYP51.
Two azole compounds used as cytostatic drugs in human
medicine, with activity based on CYP19 inhibition, were
also included in the testing to verify the lack of inhibitory
action on both human and fungal CYP51.
2. Materials and methods
2.1. Chemicals and reagents
Human CYP51 was a kind gift from Gentest (Trosken et al.,
2004b). The pCW/C.albCYP51 vector containing the cDNA
of C. albicans CYP51 was a kind gift from Prof. Waterman
(Nashville, USA) (Lepesheva et al., 2001). The pTS1 vector
containing the cDNA of C. tropicalis oxidoreductase was a
kind gift from Dr. Sanglard (Lausanne, Switzerland) (Sutter
et al., 1990). FF-MAS was a kind gift from NovoNordisk
(Gentofte, Denmark). Bitertanol, cyproconazole, flusilazole,
hexaconazole, imazalil, myclobutanil, penconazole, prochlo-
raz, propiconazole, tebuconazole, triadimefon and triadimenol
were from Dr. Ehrenstorfer (Augsburg, Germany). Epoxicona-
zole was a kind gift from the Swiss Federal Research Sta-
tion (Wa¨denswil, Switzerland). Fluconazole was kindly pro-
vided by Pfizer GmbH (Karlsruhe, Germany). Clotrimazole
was from Bufa (Uitgeest, The Netherlands). Fadrozole and
letrozole were kind gifts from Novartis Pharma AG (Basel,
Switzerland). Bifonazole, ketoconazole, itraconazole, micona-
zole and all other chemicals were of the highest grade avail-
able from Sigma/Fluka (Taufkirchen, Germany). Restriction
endonucleases and other modifying enzymes were purchased
from New England Biolabs (Beverly, USA). Bac-to-Bac® Bac-
ulovirus Expression System, pFastBacTM Dual Vector Kit, Zero
Blunt® TOPO® PCR Cloning Kit, Cellfectin® Reagent, MAX
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Efficiency® DH10BacTM Competent E. coli, M13 reverse and
M13 forward primer were from Invitrogen (Karlsruhe, Ger-
many). Reagents for bacterial growth were from Carl Roth
(Karlsruhe, Germany). The E. coli strain DH10BacTM was
from Invitrogen (Karlsruhe, Germany). SF9 insect cell cul-
ture medium SF 3 Baculo Express ICM and TNM-FH Insect
Medium were from Biozol (Munich, Germany) and BD Bio-
sciences (Whoburn, USA), respectively. Fetal calf serum was
from PAA Laboratories (Co¨lbe, Germany). DNA-isolation kits
were from Quiagen (Hilden, Germany).
2.2. Cloning and construction of expression vectors
The C. albicans CYP51 cDNA (Lepesheva et al., 2001)
was isolated from the pCW/C.albCYP51 vector after restric-
tion with BamHI and HindIII. The fragment was inserted under
control of the polyhedrin promoter into the BamHI and HindIII
digested pFastBacTM Dual Vector. The C. tropicalis oxidore-
ductase cDNA (Sutter et al., 1990) was amplified from the pTS1
vector by PCR. The upstream primer 50-ATC GCT CGA GTC
ATG GCA TTA GAT AAG-30 corresponding to the C. tropi-
calis oxidoreductase sequence from 554 to 569 bp, contained
an XhoI site (underlined). The downstream primer 50-TAA
TCA GCT GTT CAT ATT TTC CTT ACC AG-30 from 11
to 30 bp is complementary to C. tropicalis oxidoreductase
cDNA sequence from 2593 to 2612 bp. A PvuII site (under-
lined) was introduced. The resulting PCR product was isolated
from agarose gel, cloned into the Zero Blunt® TOPO® PCR
Cloning vector and sequenced, no mutations were found. The
vector containing the PCR product was digested by BspHI,
PvuII and XhoI. The DNA fragment was cloned into the PvuII
and XhoI digested pFastBacTM Dual Vector, harbouring the
cDNA of C. albicans CYP51. The C. tropicalis oxidoreduc-
tase insert is under control of the p10 promoter. Competent
MAX Efficiency® E. coli cells were transformed with the
recombinant plasmid and colonies containing the recombinant
bacmid were grown according to the Bac-to-Bac® Baculovirus
Expression System instructions. The resulting bacmid DNA
was isolated using a DNA-isolation kit. Correct insertion of
the DNA construct into the bacmid DNA was controlled by
PCR with M13 forward and M13 reverse primer according to
the manufacturers’ instructions.
2.3. Expression and preparation of membranes
Spodoptera frugiperda (SF9) cells were grown in SF 3
Baculo Express ICM Cell Culture Medium at room temper-
ature (25 ◦C) and the transfection of the bacmid DNA with
Cellfectin® was performed according to the Bac-to-Bac® man-
ual. Two sequential infection rounds produced baculovirus
stock with a titer of 2× 107 plaque forming units (pfu)/mL
as determined by plaque assay. For protein production cells
were grown in 500 mL SF 3 Baculo Express ICM Cell Culture
Medium supplemented with 10% fetal calf serum (FCS) to a
density of 3.4–4× 106 cells/mL (500 mL) in 1800 mL Fern-
bachflasks. Cells were infected at 0.01 pfu/mL and medium
was supplemented with 4mg/mL hemin from a 2 mg/mL
hemin stock solution prepared in 0.4 M NaOH/ethanol (1:1)
(Gonzalez et al., 1991). The infection was allowed to proceed
until 30–50% of the cells stained with the trypan blue dye exclu-
sion test and cells showed signs of late to very late infection.
Cells were harvested by centrifugation, washed, resuspended in
0.05 M potassium phosphate buffer pH 7.4 supplemented with
0.5 M sucrose and stored at−70 ◦C until further use. Cells were
homogenized with a Sartorius Potter S Homogeniser appara-
tus (Goettingen, Germany) and cell membranes were prepared
by centrifugation at 10,000× g and 100,000× g. Membrane
preparations (10,000× g) of four insect cell preparations were
pooled and used for incubation procedures of C. albicans
CYP51.
2.4. Analysis of membranes
The 10,000× g membrane fractions were used for the inhi-
bition studies because they contained more than 80% of the
total enzyme activity. About 10% was found in the 100,000× g
fraction and another 10% in the supernatant of the micro-
somal preparations. Protein concentration of the microsomal
preparations was determined following the method of Brad-
ford utilizing bovine serum albumin as reference. Cytochrome
P450 content of the microsomal preparations was determined
by CO difference absorbance spectra according to Omura and
Sato (1964).
2.5. CYP51 incubation assays
Stock solutions of lanosterol 1 mM and Triton X 100
16 mg/mL were prepared in isopropanol. Stock solutions and
dilution series of azoles were prepared in ethanol, except for
ketoconazole, itraconazole and miconazole where dimethyl-
sulfoxide was used. A master mix containing 975mL of 0.1 M
potassium phosphate buffer (pH 7.4), 40mL of a 50 mM
NADP+ solution, 75mL of a 66 mM magnesium chloride solu-
tion, 50mL of a 100 mM glucose-6-phosphate solution and
7mL of a 0.1 U/mL glucose-6-phosphate dehydrogenase solu-
tion was prepared. Seventy-six microliters of this solution
were mixed with 4mL of a 1:1 mix of lanosterol and Tri-
ton X 100 solution and 1mL of azole dilution. The reaction
mixture was preincubated for 5 min at 37 ◦C and the reaction
was started by addition of 20mL of C. albicans CYP51. After
40 min 100mL of isopropanol containing internal standard d6-
cholesterol (5mM) were added to stop the reaction. Protein
was removed by centrifugation at 15,000× g for 10 min. The
supernatant was transferred to low volume insert sample-vials
and 10mL were injected into the HPLC interface and analyzed
by LC–MS/MS. The LC–MS/MS analysis was performed as
described previously (Trosken et al., 2004b, 2005). For the
determination of Km and Vmax the described incubation assay
for C. albicans CYP51 was performed with dilution series of
lanosterol resulting in an inter assay substrate concentration
ranging from 1 to 50mM. The amount of isopropanol in the
incubation assay was kept constant.
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Inhibition assays with human CYP51 were performed sim-
ilar to the C. albicans CYP51 assay. For details see Trosken et
al. (2004b).
2.6. Data analysis
The area of the FF-MAS peak was normalized by the peak
area of the internal standard. The resulting relative area was
plotted against the log10 of the concentration of azole. The data
were analyzed as described (Trosken et al., 2004a). Four para-
meters were estimated by fitting the two replicate area data sets
to a probit curve: the FF-MAS relative area at azole concentra-
tion 0 and1∞, the relative area at half maximum inhibition, and
the slope of the probit curve. Statistical analysis was performed
by a nonlinear mixed-effects model fit by maximum likelihood
run on the statistics software “R” (http://www.r-project.org).
A random error was attributed to the FF-MAS relative area at
azole concentration 0, to account for differences between the
duplicates for the asymptotic background measure.
In order to generate a complete log-normal inhibition curve
for the statistical analysis, one theoretical high-dose data point
was added with full inhibition (zero-product formation) when
solubility limits did not allow experimental determination of
a second zero-product data point. In the human CYP51 assay
for fluconazole, itraconazole, fadrozole and letrozole no IC50
values could be calculated due to the low inhibitory potency
and the limited solubility.
Kinetic parameters Km and Vmax were determined by non-
linear regression analysis according to Kakkar et al. (1999, Eq.
(2)). Spearman rank correlation was calculated using the free
statistics software “R” (http://www.r-project.org).
3. Results
3.1. Analytical procedures
FF-MAS product formation and substrate concentra-
tion in the incubation assays was monitored directly
by liquid chromatography tandem mass spectrometry
(LC–MS/MS) with protein precipitation and centrifu-
gation as only sample work-up steps (Trosken et al.,
2004b). Fig. 1 depicts a LC–MS/MS chromatogram with
FF-MAS, the product of the CYP51 reaction with lanos-
terol, eluting at 8.6 min, internal standard d6-cholesterol
eluting at 8.8 min and the substrate lanosterol eluting
at 9.1 min. Complete resolution of the signals was not
required due to the double mass-selective analysis. In
comparison to the established methods of measuring
product formation of CYP51, gas chromatography mass
spectrometry or release of radiolabelled formic acid,
the utilized method has the distinct advantages of mini-
mal sample preparation and short HPLC run times. No
extraction or derivatization steps are necessary for the
analytical method, thus artefact formation is negligible.
Fig. 1. LC–MS/MS Chromatogram of an incubation of Candida albi-
cans CYP51 with lanosterol as substrate. The reaction product FF-
MAS is detected at 8.6 min retention time, the internal standard d6-
cholesterol at 8.8 min and the substrate lanosterol at 9.1 min.
3.2. Human CYP51
The P450 contents of human CYP51 supersomes
had been determined to be 20mM equivalent to
0.4 nmol P450/mg protein (Trosken et al., 2004b), result-
ing in an assay concentration of 0.1mM equivalents
to 8 pmol P450. Protein concentration of the mem-
branes was determined to be 50mg/mL, resulting in
an assay protein concentration of 0.3mg/mL. The con-
centration of organic solvents in the assay was 5%.
Product formation was linear from 10 to 40 min and
from 4 to 16 pmol P450 enzyme (data not shown).
Km and Vmax of human CYP51 were determined to
be 1.7± 0.7mM and 0.3± 0.04 pmol/min× pmol P450,
respectively. The substrate concentration for the determi-
nation of IC50 values was chosen to be 15mM equivalent
to eight times Km. In the absence of inhibitor, 1% of the
total substrate amount was metabolized within 40 min.
3.3. C. albicans CYP51 assay
Protein concentration of the membranes was
50mg/mL, the protein concentration used in the assay
was 10mg/mL. The concentration of organic solvents
in the assay was 5%. The P450 content of the
membranes was determined to be 1mM equivalent
to 0.02 nmol P450/mg protein, the enzyme concentra-
tion in the assay was 0.2mM equivalents to 20 pmol
P450 enzyme. The absorption maxima of the carbon
monoxide-bound form were located at 450 nm with
no absorption at 420 nm, indicating a fully functional
enzyme complex (data not shown).
Product formation was proportional to enzyme
amount from 5 to 40 pmol (Fig. 2) but levelled off with
time (Fig. 3). A possible explanation could be the deteri-
oration of the enzyme in the incubation mixture. Despite
the nonlinear product formation within 40 min we used
this incubation period for the determination of the IC50
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Fig. 2. FF-MAS product formation as a function of the enzyme amount
(pmol) of C. albicans CYP51 (lanosterol-14a-demethylase) in the
incubation assay.
values because the time course was reproducible and
since higher levels of product reduce the standard error
of the mass spectrometric signal.
Km and Vmax of C. albicans CYP51 at 40 min
incubation time were determined to be 7.4± 0.86mM
and 0.46± 0.019 pmol/min× pmol P450, respec-
tively. Vmax at 10 min incubation time was
1.06± 0.08 pmol/min× pmol P450. Substrate con-
Fig. 3. FF-MAS product formation as a function of time of incubation
of C. albicans CYP51 (lanosterol-14a-demethylase) membranes with
lanosterol substrate.
centration for the determination of IC50 values was
chosen to be 20mM, equivalent to approximately 2.7
times Km. Lanosterol concentrations could not be kept at
eight times Km due to solubility problems of lanosterol
in higher concentrations and effects on the substrate
turn-over. In the absence of inhibitors, approximately
20% of the substrate added was metabolized to FF-MAS
within 40 min.
Table 1
Inhibitory potency of azoles on human lanosterol-14a-demethylase (hCYP51) and CYP51 of Candida albicans (cCYP51)
Azole IC50 hCYP51 S.E. IC50 cCYP51 S.E. Ratio (h/c)
Fungicides
Bitertanol 1.30 1.29 0.059 1.22 22
Cyproconazole 22.8a 1.62 0.10 1.16 228
Epoxiconazole 1.95 1.51 0.22 1.13 9
Flusilazole 3.36 1.58 0.085 1.22 40
Hexaconazole 15.6a 1.5 0.066 1.28 236
Imazalil 36.1 1.95 0.082 1.10 440
Myclobutanil 29.0a 1.57 0.14 1.16 207
Penconazole 19.3 1.40 0.076 1.15 254
Prochloraz 5.00 1.23 0.098 1.25 51
Propiconazole 8.25 1.41 0.15 1.14 55
Tebuconazole 3.61 2.08 0.35 1.40 10
Triadimefon 9.95 1.62 0.13 1.30 77
Triadimenol 37.2a 1.36 0.33 1.27 113
Antifungal drugs
Bifonazole 0.80 1.80 0.30 1.13 3
Clotrimazole 0.85 1.47 0.091 1.12 9
Fluconazole >30 (23% inhibition)b 0.051 1.09 588
Itraconazole ≈30 (53% inhibition)b 0.039 1.13 769
Ketoconazole 0.43 1.24 0.064 1.08 7
Miconazole 0.057 1.24 0.072 1.09 0.8
Cytostatic drugs
Fadrozole ≈100 (54% inhibition)b 32.2 1.41
Letrozole >100 (11% inhibition)b 13.3 1.26
IC50 values are given in (mM) concentrations. A geometric standard error is given (×/÷) because estimates of IC50 values and standard errors were
estimated on the basis of log(concentration).
a One theoretical high-dose/zero-product point added for parameter estimation.
b No full sigmoid curve available due to limited solubility.
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3.4. IC50 values
Table 1 displays the IC50 values with geometric stan-
dard errors determined for human CYP51 and C. albi-
cans CYP51. The inhibitory potencies of azole fungi-
cides on human CYP51 ranged approximately 30-fold,
from 1.30 to 37.2mM. The most potent compounds
are bitertanol and epoxiconazole; the least potent are
imazalil and triadimenol. The IC50 values of the antifun-
gal drugs showed a wider span (500-fold) from 0.057mM
(miconazole) to >30mM (fluconazole). Miconazole was
the most potent of all azoles tested. Four of the six anti-
fungal drugs (miconazole, bifonazole, clotrimazole and
ketoconazole) were more potent than the most potent
fungicide (bitertanol). These are all imidazole com-
pounds and the older compounds on the market com-
pared to the two newer triazole compounds, fluconazole
and itraconazole. The two cytostatic drugs tested dis-
play only low inhibitory potency (≥100mM). Geometric
standard errors ranged between 1.23 and 2.08. This is
acceptable in relation to the differences of the IC50 val-
ues between the azoles.
The inhibitory potency of the fungicides on C.
albicans CYP51 ranged only six-fold, from 0.059 to
0.35mM. The most potent compounds were bitertanol
and hexaconazole; the less potent compounds were tebu-
conazole and triadimenol. The IC50 values of the antifun-
gal drugs also showed a small range of 8 from 0.039mM
(itraconazole) to 0.3mM (bifonazole). Itraconazole was
the most potent of all azoles tested.
The two cytostatic drugs displayed a 30–100-fold
lower inhibitory potency against C. albicans CYP51.
The geometric standard errors were smaller in general
than with hCYP51, ranging between 1.08 and 1.41.
The IC50 values determined for hCYP51 and cCYP51
do not correlate with each other (see Fig. 4) and they do
not correlate with log p values of the azole compounds.
Fig. 4. Plot of IC50 values for antifungal azole compounds determined
for human CYP51 (lanosterol-14a-demethylase; y-axis) and CYP51
of C. albicans (x-axis). IC50 values are given in mM concentrations.
The Spearman rank correlation coefficient ρ was −0.39
with a p of 0.12 for the correlation of hCYP51 and log p
values. For the correlation of cCYP51 and log p values
the correlation coefficient ρ was−0.31 with a p of 0.17.
The log p (or partition coefficient) describes the differ-
ential solubility of a compound in octanol and water and
is a measure of the hydrophobicity/hydrophilicity of a
substance.
A ratio of the IC50 values determined for the human
enzyme divided by the IC50 determined for the C. albi-
cans enzyme is given in the last column of Table 1. The
values for the ratio range from 0.8 (miconazole) to 769
(itraconazole). A small ratio indicates an unfavourable,
small difference between the inhibitory potency for the
fungal CYP51, compared to the human enzyme, i.e. low
selectivity. This is the case for the agriculturally used
fungicides epoxiconazole and tebuconazole and for the
antifungal drugs bifonazole, clotrimazole, ketoconazole
and miconazole.
The larger the ratio, the better the selectivity for the
fungal variant of the enzyme. Such a favourable ratio was
found for the fungicides cyproconazole, hexaconazole,
imazalil, myclobutanil and penconazole. Of the anti-
fungal drugs, only fluconazole and itraconazole showed
such a desirable high ratio.
4. Discussion
C. albicans CYP51 (Lepesheva et al., 2001) and C.
tropicalis cytochrome P450 oxidoreductase (Sutter et al.,
1990) were co-expressed in the baculovirus system to
obtain a functional enzyme complex with a similar back-
ground as the human enzyme available from BD Gentest.
Thus the inhibitory potencies of azoles on human and
fungal CYP51 could be determined in equivalent sys-
tems.
C. albicans CYP51 has been expressed before in
Saccharomyces cerevisiae, purified on chromatographic
columns and reconstituted by Lamb et al. (1997b,
1999a,b). The Km values and respective Vmax values
are given in Table 2 and are compared to the values
determined for the C. albicans CYP51–C. tropicalis oxi-
doreductase construct. The Km values reported are three
to four times higher compared to the value determined
for the construct described above. Km is a measure of
the affinity of a substrate to an enzyme and is indepen-
dent of the enzyme amount used.The difference between
the literature value and the one described above can be
in part explained by the fact that Lamb et al. used a
different expression system namely S. cerevisiae. C. albi-
cans CYP51 was expressed alone and was later recon-
stituted with a rabbit oxidoreductase. Additionally the
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Table 2
Kinetic parameters Km and Vmax of heterologously expressed C. albi-
cans lanosterol-14a-demethylase (cCYP51)
Km (mM) Vmax
Our values 7.4 0.46 mol product/
min×mol P450
Lamb et al. (1999b)a 20.8 0.15 mol product/
min×mol P450
Lamb et al. (1999a)b 21 0.24± 0.04 mol product/
min×mol P450
Lamb et al. (1997b)a 29.4 0.15 mol substrate converted/
min×mol P450
Comparison of our values (crude membranes) with literature values
for purified enzyme.
a Catalytic activity was achieved by reconstitution of purified
enzyme with rabbit NADPH oxidoreductase (Lamb et al., 1997b,
1999b).
b Catalytic activity was achieved by reconstitution of purified
enzyme with yeast cytochrome b5 and NADH cytochrome b5 reductase
or with yeast oxidoreductase (Lamb et al., 1999a).
non-purified enzyme shows a higher affinity to its sub-
strate than the purified ones described in the literature.
In the living organism cytochrome P450 enzymes and
the respective oxidoreductase form a complex anchored
in the cell membrane. By purifying the enzyme it is
removed from its “natural” environment. This could have
an influence on the enzyme conformation and thus on its
substrate affinity indicated by the higher Km values.
The Vmax value determined for the described non-
purified enzyme (40 min incubation time) is not com-
parable to one of those reported in the literature. The
literature values are two to three times lower. Differences
could be explained by the fact that different analyti-
cal methods were used to monitor product formation
and that for the lowest Vmax value reported substrate
turn-over was determined rather than product formation.
Table 4
Comparison of our IC50 values for human lanosterol-14a-demethylase
(hCYP51) with those reported in the literature
Substance This manuscript Lamb et al. (1999b)a
Itraconazole ≈30 (53% inhibition) 0.61
Ketoconazole 0.43 0.58
a Purified human CYP51, formic acid release assay (Lamb et al.,
1999b).
Further explanations for the differences found both for
Km and Vmax could be the different analytical procedures
used to calculate both constants (nonlinear model versus
double-inverse linear Lineweaver–Burk plots) and the
uncertainty about the error of two of the three literature
values.
Human CYP51 has also been heterologously
expressed in yeast and purified (Lamb et al., 1999b).
Catalytic activity was reconstituted by addition of rab-
bit NADPH oxidoreductase and Km and Vmax were
determined to be 29.4mM and 0.474 pmol product/
min× pmol P450. Differences to the human enzyme
used in this manuscript can be explained by the same
arguments brought forward for the differences between
the C. albicans CYP51 described and literature values,
namely a different expression system, reconstitution ver-
sus native enzyme and co-expression.
4.1. Comparison with literature IC50 values
Lamb et al. (1999b) determined IC50 values for keto-
conazole and itraconazole with a formic acid release
assay. They found a less than 10-fold difference between
the fungal and the human enzyme (Tables 3 and 4). The
values for ketoconazole could be reproduced here on
both enzymes. For itraconazole, we found a similar IC50
Table 3
Comparison of our IC50 values for C. albicans lanosterol-14a-demethylase (cCYP51) with those reported in the literature
Substance This manuscript Lamb et al.
(1999b)a
Lamb et al.
(2000)b
Lamb et al.
(1997a)b
Vanden Bossche et al. (1987), Vanden
Bossche and Koymans (1998)c
Imazalil 0.082 0.05
Penconazole 0.076 0.019
Propiconazole 0.15 0.061
Bifonazole 0.30 1.170
Clotrimazole 0.091 0.036
Fluconazole 0.051 0.053 0.249
Itraconazole 0.039 0.08 0.0076 0.031
Ketoconazole 0.064 0.06 0.008 0.006 0.03
Miconazole 0.072 0.076
a Purified C. albicans CYP51, formic acid release assay (Lamb et al., 1999b).
b Cell free biosynthesis of ergosterol from [2-14C] mevalonate with C. albicans (Lamb et al., 1997a, 2000).
c Inhibition of CO-binding to central heme iron using C. albicans membranes (Vanden Bossche et al., 1987; Vanden Bossche and Koymans, 1998).
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value for C. albicans, while the human variant of the
enzyme showed a much higher IC50 value (30mM ver-
sus 0.61mM by Lamb et al. (1999b)). No explanation
can be given for this difference.
Table 3 includes literature data based on the use of
[2-14C] mevalonate as substrate. This compound is a pre-
cursor of lanosterol that is synthesized in situ in the assay.
IC50 values of 0.053mM for fluconazole, 0.0076mM for
itraconazole and 0.008–0.006mM for ketoconazole were
found (Lamb et al., 1997a, 2000). The values for itra-
conazole and ketoconazole are a factor of 5–10 below
those reported by the same group using the formic acid
release assay and those reported in this manuscript. An
explanation could be that the lanosterol substrate con-
centration is not known in the [2-14C] mevalonate assay.
However, IC50 values are dependent on the substrate con-
centration. Another interpretation of the difference in
IC50 values is that the azoles inhibited not only CYP51
but also enzymes necessary for the production of lanos-
terol from mevalonate.
Vanden Bossche et al. reported IC50 values for a vari-
ety of azole compounds using membranes isolated from
C. albicans (Table 3) (Vanden Bossche et al., 1987;
Vanden Bossche and Koymans, 1998). Numerical values
fit well to the ones determined here for some examples,
e.g. imazalil, itraconazole, ketoconazole and micona-
zole. For others the difference to our values and those
of Lamb’s was by a factor of up to 5 (fluconazole).
The inhibitory potency was assessed by the inhibition of
CO-binding to the central heme iron of CYP51. It is ques-
tionable whether this assay can fully assess the inhibitory
potency of mixed-type or non-competitive inhibitors,
which could explain the observed differences.
Lamb et al. postulate that in crude membrane fractions
of rat or human liver azole compounds are scavenged by
other microsomal enzymes present. Thus higher con-
centrations of inhibitor are necessary and higher IC50
values result. Trzaskos and Henry reported already in
1989 that the sensitivity of rat CYP51 towards flusi-
lazole is enhanced when the enzyme is partially puri-
fied from rat hepatic microsomes (Trzaskos and Henry,
1989). By expressing both human CYP51 and C. albi-
cans CYP51 in the same system a similar protein back-
ground is present in both incubation assays. Further-
more, the level of cytochrome P450 enzymes expressed
in insect cell lines is much lower than in mammalian
liver microsomes. Scavenging of azole inhibitor by other
cytochrome P450 enzymes was therefore less of a prob-
lem in our assays.
The assays established here allowed for an optimal
comparison of inhibitory potencies of azole compounds
towards human and fungal CYP51. For a number of com-
pounds, e.g. epoxiconazole, tebuconazole, bifonazole,
clotrimazole, ketoconazole and miconazole, the differ-
ence between the inhibition of human CYP51 and fungal
CYP51 is smaller than by a factor of 10. For imazalil,
fluconazole and itraconazole, on the other hand, the dif-
ference between the inhibition of fungal and human
enzyme is by more than a factor of 400, indicating high
specificity for the fungal enzyme compared to the human
analogue. This is a desirable feature for all antifungal
azole compounds since production of FF-MAS and T-
MAS in humans should not be inhibited.
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